BET-BAY 002 (S enantiomer) is primarily utilized in the field of medicinal chemistry and drug development. It serves as a potent and selective inhibitor of bromodomain and extra-terminal (BET) proteins, which play a critical role in regulating gene expression. This compound is particularly valuable in cancer research, where it is used to study the effects of BET protein inhibition on tumor growth and proliferation. By targeting BET proteins, it helps in understanding and potentially disrupting the pathways that drive cancer progression. Additionally, it is employed in preclinical studies to evaluate its efficacy and safety as a potential therapeutic agent for various cancers, including leukemia and solid tumors. Its enantiomeric purity ensures specificity in binding and activity, making it a crucial tool for advancing targeted cancer therapies.